SCHEMBL4202147

SCHEMBL4202147

CC(CC1CCCCC1)NCc1ccccc1NC(=O)N1CCN(S(=O)(=O)c2ccc(Cl)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
KDM4E B2RXH2 2/20 0.54
HPGD P15428 1/20 0.54
HSD17B10 Q99714 1/20 0.54
KMT2A Q03164 4/20 0.50
MEN1 O00255 1/20 0.50
NPSR1 Q6W5P4 2/20 0.47
PKM P14618 2/20 0.46
LMNA P02545 4/20 0.43
GAA P10253 1/20 0.43
POLB P06746 2/20 0.43
CNR1 P21554 1/20 0.42
TSHR P16473 1/20 0.42
ALOX12 P18054 1/20 0.42
HTT P42858 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4202203 0.93 KMT2A (0.49) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL4190300 0.92 PKM (0.49) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL4192826 0.86 MAPT (0.45) ALDH1A1SMN1; SMN2KDM4EKMT2ALMNA
SCHEMBL27725854 0.85 CNR1 (0.38) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL4197733 0.84 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2HPGDKMT2AMEN1
SCHEMBL4708549 0.83 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL4185987 0.83 KDM4E (0.46) ALDH1A1KDM4EHSD17B10KMT2AMEN1
SCHEMBL4195114 0.81 LMNA (0.43) ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1
SCHEMBL4190891 0.81 LMNA (0.43) ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1
SCHEMBL4195525 0.81 KDM4E (0.50) ALDH1A1SMN1; SMN2KDM4EHSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP claimed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US claimed
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP disclosed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US disclosed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US disclosed
EP-1879877-A2 ANTIMICROBIAL AGENTS Ranbaxy Laboratories Limited (IN) 2008-01-23 EP disclosed
WO-2006117762-A2 ANTIMICROBIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215764-A1 Antimicrobial agents TUFM, RPS17, HARS1 ALDH1A1 2744/4885SMN1; SMN2 3369/4885KDM4E 3328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.